Vanda Pharmaceuticals (VNDA) news
Recent news
Vanda Pharmaceuticals - No new safety signals identified in phase III study for Hetlioz
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has reported that no new safety signals were identified in a Phase III study evaluating Hetlioz (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD) in individuals who are completely blind. The open-label, long-term safety study,…
AInvest Wire · Sep 29, 2026Vanda Pharmaceuticals - Phase III study met primary endpoint with 37.1 minute sleep onset shift vs placebo
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) recently announced that its drug HETLIOZ® (tasimelteon) demonstrated a 37.1-minute shift in sleep onset compared to placebo in a Phase III clinical study, meeting its primary endpoint. The study, which focused on patients with primary insomnia, showed…
AInvest Wire · Sep 29, 2026Vanda Pharmaceuticals Inc: Oppenheimer initiates coverage with outperform rating; price target $10
AInvest Wire · Sep 23, 2026Vanda Pharmaceuticals - imsidolimab BLA for GPP under FDA review with target action date December 12, 2026
AInvest Wire · Jul 16, 2026Vanda Pharmaceuticals: EMA positive opinion for orphan drug designation of imsidolimab for generalized pustular psoriasis - A
AInvest Wire · Jul 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.